BGB-108 / BeiGene  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BGB-108 / BeiGene
DUBHE-L-303, NCT05690945: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Not yet recruiting
3
650
NA
QL1706, PSB205, Tilesizumab, BGB-108
Qilu Pharmaceutical Co., Ltd.
Lung Cancer
06/25
06/25

Download Options